NCT07393672 · Washington State University
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
What this study is about
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
View original scientific description
The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.
Interventions
DRUG
Hemp-derived cannabinoids
Participants will be administered a legal product with hemp-derived cannabinoids and terpenes.
DRUG
Placebo
Participants will be administered a placebo
Primary outcome measures
Depression Monthly Assessment: Center for Epidemiologic Studies Depression Scale (CES-D)
Time frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13.
At the end of each monthly Zoom session, participants will be sent a survey link including the Center for Epidemiologic Studies Depression Scale (CES-D). Participants will complete the CES-D after each zoom session, including the first session, the baseline session after four week, and after both phase 1 and phase 2.
Anxiety Monthly Assessment: Beck Anxiety Inventory
Time frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13.
At the end of each monthly Zoom session, participants will be sent a survey link including the Beck Anxiety Inventory (BAI). Participants will complete the BAI after each zoom session, including the first session, the baseline session after four week, and after both phase 1 and phase 2.
Perimenopausal Depression Monthly Assessment: Meno-D
Time frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13.
At the end of each monthly Zoom session, participants will be sent a survey link including the Meno-D. Participants will complete the Meno-D after each zoom session, including the first session, the baseline session after four week, and after both phase 1 and phase 2.
Emotional/Mental Symptoms Daily Assessment
Time frame: Emotional/mental symptoms will be assessed during each session (morning and night) of the daily EMA assessments, for the 3 month duration of the study.
During each EMA session (twice daily), participants will be asked to indicate emotional/mental symptoms they have experienced since the last time they completed the survey. Possible symptoms include: new or worsening anxiety; new or worsening depression/crying; loss of interest in most things; fatigue or loss of energy; diminished self-esteem; mood swings; irritability; brain fog. They will also have the opportunity to write in other symptoms experienced. For each endorsed symptom, participants will be asked to rate the severity (on a 0 to 10 visual analog scale) and the degree to which that symptom interferes with their life (on a 0 to 10 visual analog scale)
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- designated female at birth
- 40-60 years of age
- able to give informed consent (no intellectual disability)
- stable pharmacotherapeutic regimen, no change in the past 3 months
- abstinent from regular cannabis use (\<1x/month) for past year, and willing to abstain from use for 3 months
- abstinent for supplements, don't add any supplements (no changes in past 3 months)
- own a smartphone
- have access to Zoom on a secure, stable internet connection
- perimenopausal or menopausal
Exclusion criteria
- currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication
- severe depression, neurovegetative symptoms, or current suicidality
- psychosis or family history of psychosis
- pregnant or breastfeeding
- chemotherapy
- hypotension
- drug testing for work or other reasons
- illicit drug use in past 3 months (cannabis not illicit)
- heavy alcohol use (4 drinks more than 4x/week)
- international/air travel planned for more than one week in the next 3 months
- cocounut allergy
Where
- Pullman, Washington
Collaborators
Terra Mater Botanicals Pty Ltd
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Mar 10, 2026 · Source of record for eligibility and locations